ARTICLE SUMMARY:
CDRH director Jeff Shuren on lessons learned from COVID and a long-term vision for FDA’s device program; MDMA’s Mark Leahey on what the Biden Administration and the new Congress portend for the medtech industry; CVRx’s early focus on reimbursement has paid off with NTAP approval; Pandemic-driven changes to clinical trials are here to stay, says PRA Health Sciences’ Isaac Rodriguez-Chavez. These stories and more in the current issue of Market Pathways.
